Skip to main content

Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4B deal

By Reuters  
   August 10, 2022

(Reuters) - Pfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics, as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment.

Full story

Get the latest on healthcare leadership in your inbox.